RATIONAL APPROACHES TO THE TREATMENT OF DYSLIPIDEMIA WITH DIFFERENT TOTAL CARDIOVASCULAR RISK AND ACUTE CORONARY SYNDROME
https://doi.org/10.20996/1819-6446-2014-10-5-540-547
Abstract
Approaches to the total cardiovascular risk calculation based on the actual clinical recommendations are presented as well as the application of risk categories for the choice of strategy of dyslipidemia correction. The use of statins as lipid-lowering therapy in patients with acute coronary syndrome and coronary angioplasty are also discussed.
About the Authors
N. V. Perova
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
V. A. Metelskaya
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
References
1. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217S :S1-S44.
2. Еuropean guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 Suppl 2:E1-40.
3. Pencina M.J., Agostino R.B., Larson S.M. Predicting the 30-Year Risk of cardiovascular disease: The Framingham Heart Study. Circulation 2009;119:3078-84.
4. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35(2):139-51.
5. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005;59(2):239-52.
6. Chang S.M., Yasbek N., Lakks N.M. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004;62:193-7.
7. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention. Results of the ARMYDAACS Randomized Trial. J Am Coll Cardiol 2007;49:1272-8.
8. Di Sciascio G., Patti G., Pasceri V., et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54;558-65.
9. RSC, NSA, RSCR expert opinion to optimize of statin therapy in clinical practice. Ration Pharmacother Cardiol 2011; 7 (1): 107-9. Russian (Заключение экспертов ВНОК, НОА и РОСОКР по оптимиза-ции терапии статинами в клинической практике. Рациональная Фармакотерапия в Кардиологии 2011; 7(1):107-9).
10. Lablanchea J.M., Leoneb A., Merkelyc B., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein AI ratio in patients with acute coronary syndrome: Results of the CENTAURUS study. Arch Cardiovasc Dis 2010; 103:160-9.
11. Zadionchenko VS, Shehyan GG, Shahray NB, et al. Effect of rosuvastatin on lipid metabolism, microcirculation and central hemodynamics in patients with acute coronary syndrome. Consilium Medicum 2011; 13 (5): 4-8. Russian (Задионченко В.С., Шехян Г.Г., Шахрай Н.Б. и др. Влияние розува-статина на липидный обмен, микроциркуляцию и показатели центральной гемодинамики у боль-ных с острым коронарным синдромом. Consilium Medicum 2011;13(5):4-8).
12. Otagiri К., Tsutsui H., Kumazaki S. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome – analysis using integrated backscatter IVUS (ELAN Study). Circ J 2011;75:633-41.
13. Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the ESC and the EACTS Developed with the special contribution of the EAPCI. Eur Heart J 2010;31: 2501-55.
Review
For citations:
Perova N.V., Metelskaya V.A. RATIONAL APPROACHES TO THE TREATMENT OF DYSLIPIDEMIA WITH DIFFERENT TOTAL CARDIOVASCULAR RISK AND ACUTE CORONARY SYNDROME. Rational Pharmacotherapy in Cardiology. 2014;10(5):540-547. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-5-540-547
Views:
686
.jpg)
Email this article 